Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
Want to see APRE full AI Analyst Report?
APRE Stock Chart & Stats
$1.00
-$0.03(-0.72%)
At close: 4:00 PM EST
$1.00
-$0.03(-0.72%)
Day’s Range― - ―
52-Week Range$0.55 - $2.22
Previous CloseN/A
Volume2.88K
Average Volume (3M)55.77K
Market Cap
$11.52M
Enterprise Value-$40.42M
Total Cash (Recent Filing)$46.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Aug 06, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding12,382,776
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-3.51
Enterprise Value/Revenue-342.25
Enterprise Value/Gross Profit22.46
Enterprise Value/Ebitda3.22
Forecast
1Y Price Target
$4.07Price Target Upside306.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$1.07M
Bulls Say, Bears Say
Bulls Say
Early Clinical Proof-of-concept (APR-1051)Early, reproducible tumor responses and tolerability for APR-1051 provide durable proof-of-concept, raising the program’s probability of advancement into later-stage trials, supporting enrollment expansion and potential partnerships or investigator interest that materially strengthen the company’s long-term development pathway.
Secured Financing Extending RunwayA materially oversubscribed $30M financing and reported $46.5M cash extend operational runway into early 2028, materially reducing immediate refinancing pressure and giving management time to generate additional clinical readouts and strategically advance APR-1051 without urgent dilution-driven decisions.
Low Financial Leverage (no Debt)Effectively zero debt lowers refinancing and interest-rate risk, preserving financial optionality for partnering, acquisitions, or non-dilutive financings. This structural flexibility supports long-term R&D investment decisions and reduces fixed-cost pressure on a development-stage biotechnology company.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow signal ongoing reliance on external capital to fund R&D. Even with current cash, sustained burn risks needing additional financing if trials extend, which can dilute shareholders and constrain strategic flexibility over the medium term.
Ongoing Losses And Volatile RevenueDeep and persistent operating losses with volatile, declining revenue reflect a lack of sustainable commercial cash flow. This structural unprofitability limits the firm’s ability to self-fund development, keeps returns on equity negative, and increases dependency on external capital over multiple quarters.
Program Execution Uncertainty (ATRN-119 Pause)Pausing ATRN-119 monotherapy enrollment increases timeline and execution risk: shifting to combination strategies requires new study designs, partner negotiations, and additional data, raising the probability of delays, higher costs, and uncertain regulatory or clinical outcomes for that program.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $2.22 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $11.52M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 68 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.212 by -$0.008.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.18.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 12,382,776 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.212. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$4.07
▲(306.67% Upside)
Technical Analysis
Ownership Overview
6.30% Insiders
0.86% Mutual Funds
15.36% Other Institutional Investors
77.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---